RBC Capital analyst Walter Spracklin maintains Bombardier (TSX:BBD) with a Outperform and raises the price target from C$1.5 to C$2.
Concert Pharmaceuticals Q2 EPS $0.16 Up From $(0.41) YoY, Sales $32.02M Up From $6.39M YoY
Concert Pharmaceuticals (NASDAQ:CNCE) reported quarterly earnings of $0.16 per share. This is a 139.02 percent increase over losses of $(0.41) per share from the same period last year. The company reported $32.02